Atezolizumab + bevacizumab shows benefit in met renal CA
(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presen
Updated on: March 30,2024
13

Atezolizumab + bevacizumab shows benefit in met renal CA
(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presen
Updated on:March 30,2024
13
